CIAM
ZYBT

Caitong International Asset Management’s Zhengye Biotechnology Holding ZYBT Stock Holding History

Caitong International Asset Management’s Portfolio ZYBT Stock Details ZYBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Hold
1
– – ﹤0.01% 2941
2026
Q1 		$1 Hold
1
– – ﹤0.01% 2534
2025
Q4 		$1 Hold
1
– – ﹤0.01% 1834
2025
Q3 		$3 Buy
+1
New +$7 ﹤0.01% 1866

Other funds holding ZYBT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Caitong International Asset Management's ZYBT Position: Q2 2026 in Review

Caitong International Asset Management held its Zhengye Biotechnology Holding (ZYBT) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

Caitong International Asset Management first reported a position in ZYBT in Q3 2025 and has held it in 4 quarters since. The position peaked at $3 in Q3 2025. 6 funds tracked by Wall St. Rank hold ZYBT as of Q2 2026.

  • Caitong International Asset Management held 1 share of Zhengye Biotechnology Holding worth $1 as of Q2 2026.
  • Caitong International Asset Management left its Zhengye Biotechnology Holding share count unchanged in Q2 2026.
  • Zhengye Biotechnology Holding made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2941 holding.
  • Caitong International Asset Management first reported a position in Zhengye Biotechnology Holding in Q3 2025 and has held it in 4 quarters since.
  • Caitong International Asset Management's Zhengye Biotechnology Holding position peaked at $3 in Q3 2025.
  • 6 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.